AT

Atlas Ventures

Editorial Pick Active

Researched and published by the startup.ph editorial team from public sources — not a self-submitted profile.

Atlas Venture

VC Fund 📍 United States, North America

About Atlas Ventures

Atlas Venture (the firm's own branding uses the singular "Venture," though it is commonly referred to as "Atlas Ventures") is a venture capital firm headquartered in Cambridge, Massachusetts. It traces its roots to 1980, when it was founded in Amsterdam by Michiel de Haan as a subsidiary of NMB Bank (now part of ING Group), before later relocating its center of gravity to the United States. The firm has raised its most recent flagship vehicle, Fund XIV, at $450 million (closed December 2024), and reports roughly $2.7 billion in assets under management with about 29 employees operating from a single Cambridge office today, having previously also maintained offices in London, Paris, Munich, and Seattle.

In October 2014, Atlas underwent a major strategic shift, exiting technology investing entirely to focus exclusively on biotechnology. Its technology-focused investment team spun out to form a separate firm, Accomplice, to continue backing IT and software startups. Atlas Venture has no confirmed Philippine or Southeast Asian investment activity based on sources reviewed for this profile — it operates as a U.S.- and Europe-oriented life sciences investor.

Investment Thesis

Atlas Venture invests almost exclusively in seed and early-stage biotechnology companies, frequently co-founding and incubating startups directly out of its own network of scientist-entrepreneurs rather than only backing companies that approach it externally. It complements this early-stage focus with an "Opportunity Fund" strategy that provides growth-stage follow-on financing to existing portfolio companies as they mature.

Portfolio Companies

Alnylam Pharmaceuticals, Exelixis, Intellia Therapeutics, Bicycle Therapeutics, Kymera Therapeutics, Dyne Therapeutics